Welcome to our dedicated page for BOUNDLESS BIO SEC filings (Ticker: BOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating a single clinical milestone inside Boundless Bio鈥檚 dense SEC reports can feel like searching for ecDNA in a healthy cell. Trial readouts hide in 8-K exhibits, while cash-runway clues lurk deep in footnotes鈥攑roblems every biotech investor knows too well.
Stock Titan solves that research headache. Our AI dissects Boundless Bio SEC filings explained simply, turning hundreds of pages into concise highlights. Whether you need a Boundless Bio quarterly earnings report 10-Q filing breakdown, a Boundless Bio annual report 10-K simplified overview of R&D spend, or a Boundless Bio 8-K material events explained alert on fresh trial data, we surface the facts the moment they hit EDGAR.
All documents are here鈥攑rospectuses for future raises, Boundless Bio proxy statement executive compensation details, and real-time Boundless Bio Form 4 insider transactions. Use our platform to:
- Track Boundless Bio insider trading Form 4 transactions and spot buying trends.
- Receive Boundless Bio earnings report filing analysis within minutes of publication.
- Monitor Boundless Bio executive stock transactions Form 4 with instant notifications.
For professionals who value speed and clarity, understanding Boundless Bio SEC documents with AI means fewer late nights parsing clinical jargon and more time acting on insight. From the first CHK1 data point to the latest capital raise, Stock Titan鈥檚 real-time engine keeps you ahead of the market.
Overview: Boundless Bio (Nasdaq: BOLD) is a clinical-stage precision oncology company focused on ecDNA-directed therapeutics (ecDTx). The company reported no revenue and an accumulated deficit of $232.9 million as of June 30, 2025.
Key financials (as of/for June 30, 2025): Cash and cash equivalents of $14.7 million, short-term investments of $112.5 million (total cash, cash equivalents and short-term investments of $127.1 million). Net loss was $31.4 million for the six months ended June 30, 2025 and $15.7 million for the quarter ended June 30, 2025. Operating cash used was $26.4 million for the six months ended June 30, 2025.
Operational and program updates: Company completed portfolio prioritization May 23, 2025, discontinued certain single-agent arms of BBI-355 and halted escalation of BBI-825 dosing, opened a BBI-355/BBI-825 combination arm in the POTENTIATE trial, selected kinesin degrader development candidate BBI-940 with an expected IND submission in H1 2026, and implemented a workforce reduction of approximately one-third. Management expects existing cash, cash equivalents, and short-term investments to fund operations into the first half of 2028.
Boundless Bio director Christine Brennan received a stock option grant on June 23, 2025. Key details of the transaction:
- Granted 16,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The grant was executed under direct ownership, and the filing was signed by Jessica Oien as attorney-in-fact for Christine Brennan. This equity compensation aligns with standard director compensation practices and aims to align the director's interests with shareholders.
Boundless Bio, Inc. (NASDAQ: BOLD) filed a Form 4 disclosing that director James Christensen received a new stock-option grant on 06/23/2025. The award covers 16,000 options with an exercise price of $1.03 per common share and an expiration date of 06/22/2035. The option vests in substantially equal monthly installments over the 12 months following the grant date. Any unvested portion will accelerate and vest on the date of the company鈥檚 next annual shareholder meeting if that meeting occurs before 06/23/2026, provided the director remains on the board.
The filing shows that these options represent the entirety of Christensen鈥檚 reported derivative holdings after the transaction; no open-market purchases, sales, or other equity awards were reported. Ownership is listed as direct, indicating the director personally holds the options rather than through a trust or other entity. No non-derivative (common-stock) transactions were disclosed.
Because the filing reports a routine board compensation grant rather than a discretionary insider purchase or sale, it is typically regarded as a neutral governance event for valuation purposes. There is no accompanying financial guidance, earnings data, or indication of broader corporate actions.
Director Jennifer Lew of Boundless Bio received a stock option grant on June 23, 2025. The grant consists of options to purchase 16,000 shares of common stock at an exercise price of $1.03 per share.
Key details of the stock option grant:
- Exercise price: $1.03 per share
- Expiration date: June 22, 2035
- Vesting schedule: Monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision: Any unvested portion will vest at next annual stockholder meeting if occurring before June 23, 2026
- Vesting contingent on continued board service
The Form 4 was filed by Jessica Oien as attorney-in-fact for Jennifer Lew, reporting a direct ownership form of the derivative securities.
Director Jonathan E. Lim of Boundless Bio received a stock option grant on June 23, 2025, representing a significant insider transaction. The key details include:
- Granted 24,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The grant was executed under direct ownership, with Jessica Oien signing as attorney-in-fact. This equity compensation aligns with standard director compensation practices and demonstrates the company's commitment to retaining board talent through long-term incentives.
Form 4 Overview: On 06/23/2025, Boundless Bio, Inc. (ticker BOLD) filed a Form 4 disclosing a grant of derivative securities to director and 10% owner Kristina Burow.
- Security granted: Stock option (right to buy)
- Quantity: 16,000 options
- Exercise price: $1.03 per share
- Vesting schedule: Monthly over 12 months beginning 06/23/2025; any unvested portion accelerates to the next annual shareholder meeting if earlier.
- Expiration: 06/22/2035
- Ownership form after transaction: Direct (16,000 derivative securities)
No non-derivative share transactions were reported. The filing represents routine director compensation rather than an open-market purchase, and it does not include financial performance metrics or earnings data.
Boundless Bio director Nancy Whiting received a stock option grant on June 23, 2025, according to a Form 4 filing. The key details of the transaction include:
- Granted 16,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The options were granted as part of director compensation and are subject to continued service on the company's board. The transaction was executed under direct ownership, with Jessica Oien signing as attorney-in-fact for Nancy Whiting.
Boundless Bio, Inc. (Nasdaq: BOLD) filed a Form 8-K detailing the results of its 23 June 2025 annual meeting of stockholders.
- Director elections: Class I nominees Christine Brennan, Ph.D. (9,252,440 for / 5,046,258 withheld) and Nancy Whiting, Pharm.D. (9,758,214 for / 4,540,484 withheld) were elected to serve until the 2028 annual meeting; 3,540,518 broker non-votes were recorded for each candidate.
- Auditor ratification: Shareholders ratified KPMG LLP as independent registered public accounting firm for fiscal 2025 with 17,791,309 votes for, 47,807 against and 100 abstentions.
No other matters were brought before shareholders and no additional material disclosures were made.
FAQ
What is the current stock price of BOUNDLESS BIO (BOLD)?
What is the market cap of BOUNDLESS BIO (BOLD)?
